Story perspectives

New Drug Combo Boosts AML Treatment but Survival Rates Low

12/31/2025

Summary

Story summary

Oregon Health & Science University researchers found that combining venetoclax with palbociclib increases leukemia-fighting activity in acute myeloid leukemia (AML) patients unresponsive to standard treatments.
The study analyzed samples from over 300 patients and confirmed findings in human tissue and mouse models.
Although the regimen improved initial responses, five-year AML survival remains low at 25%–40%.
The team says clinical trials are needed to further test the combination due to resistance.

1 of 1

Story summary

Oregon Health & Science University researchers found that combining venetoclax with palbociclib increases leukemia-fighting activity in acute myeloid leukemia (AML) patients unresponsive to standard treatments.
The study analyzed samples from over 300 patients and confirmed findings in human tissue and mouse models.
Although the regimen improved initial responses, five-year AML survival remains low at 25%–40%.
The team says clinical trials are needed to further test the combination due to resistance.